 Baudax Bio, Inc. BXRX, a pharmaceutical company focused on therapeutics for acute care settings, today announced that it has closed on a credit facility of up to 50 million from funds managed by Marathon Asset Management, a global credit solutions partner. JMP Securities LLC acted as exclusive financial advisor and sole placement agent to Baudax on this transaction. This strategic non-dilutive financing represents our strong belief in the future commercial prospects for ANJESO as a new, intravenous non-opioid option for the management of moderate to severe pain, said Gerri Henwood, CEO of Baudax Bio. 